ABBV Stock Risk & Deep Value Analysis
AbbVie Inc
Healthcare • Drug Manufacturers - General
DVR Score
out of 10
What You Need to Know About ABBV Stock
We analyzed AbbVie Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ABBV through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
ABBV Risk Analysis & Red Flags
What Could Go Wrong
AbbVie's future growth relies heavily on the continued success and market share expansion of its next-generation immunology drugs, Skyrizi and Rinvoq, which together are projected to reach over $32 billion in annual revenue by 2027. If these key products face stronger-than-anticipated competition from new treatments or biosimilars, or fail to gain new indications as expected, it could significantly impact AbbVie's ability to offset Humira's patent cliff and sustain its current growth trajectory.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Low
Competitive
High
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Insider Selling Activity: 4 insider sales and 0 purchases in the last 6 months, as per the Quiver source, indicates a lack of insider conviction at current price levels.
- ⚠
High R&D Investment for Uncertain Returns: While inherent to pharma, the substantial R&D expenditure (not quantified here, but historically high for ABBV) carries inherent risk with no guarantee of successful product development or regulatory approval.
- ⚠
GAAP EPS Volatility: The Q1 2026 GAAP diluted EPS of $0.39, a -45.8% YoY decline due to an unfavorable $0.41/share IPR&D impact, highlights the potential for non-cash charges to significantly impact reported profitability.
Upcoming Risk Events
- 📅
Q2 2026 Earnings Miss (Estimated late July/early August 2026): A significant miss on revenue or adjusted EPS guidance, particularly a slowdown in Skyrizi/Rinvoq growth below current expectations, could lead to downward revisions in full-year guidance and stock price weakness.
- 📅
Increased Competitive Pressure in Immunology (Ongoing - 2027): Faster-than-expected market entry or superior efficacy data from competitors' immunology drugs or biosimilars to Skyrizi/Rinvoq could erode market share and impact the ~$32B combined revenue forecast for these drugs by 2027.
When to Reconsider
- 🚪
Exit if Immunology segment operational revenue growth (currently +12.4%) falls below 5% for two consecutive quarters, indicating significant competitive erosion or pipeline issues.
- 🚪
Sell if full-year adjusted EPS guidance is revised downwards by more than 5% from the current midpoint of $14.18, suggesting a deterioration in the company's earning power.
Unlock ABBV Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does AbbVie Inc (ABBV) Do?
Market Cap
$381.10B
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
55,000
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Visit AbbVie Inc WebsiteInvestment Thesis
If AbbVie's key immunology drugs, Skyrizi and Rinvoq, continue to expand their market share globally and achieve their projected combined annual revenue of over $32 billion by 2027, complemented by successful advancements in its neuroscience and oncology pipelines, then the company will sustain mid-to-high single-digit revenue growth and generate substantial free cash flow, supporting its robust dividend and strategic M&A, thereby offering stable long-term returns for income-focused investors, but not exponential 10x growth.
Is ABBV Stock Undervalued?
Unlock the full AI analysis for ABBV
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ABBV Price Targets & Strategy
12-Month Target
$260.00
Bull Case
$294.00
Bear Case
$190.00
Valuation Basis
Based on a 18.3x forward P/E applied to the midpoint of the FY2026 adjusted EPS guidance ($14.18), consistent with median analyst target and historical premium for stable pharma.
Entry Strategy
Consider dollar-cost averaging on pullbacks towards the $200-$205 range, which has shown historical support. A dip towards the 200-day moving average (not provided, but typically lower than current price) would present a favorable entry for long-term holders.
Exit Strategy
Take profit at the median analyst target of $260.0, with a stop-loss order placed at $190.0 to protect against significant downside or unexpected pipeline failures.
Portfolio Allocation
1-3% for a moderate-risk portfolio focused on income and stability; not suitable for aggressive high-growth portfolios seeking 10x returns.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is ABBV Financially Healthy?
Valuation
P/E Ratio
104.84
Forward P/E
14.42
PEG Ratio
1.77
Price/Book
51.13
Price/Sales
5.59
Profitability
Gross Margin
72.03%
Operating Margin
24.41%
Net Margin
5.79%
Return on Equity
95.59%
Revenue Growth
9.50%
EPS
$2.05
Balance Sheet
Current Ratio
0.67
Quick Ratio
0.41
Debt/Equity
20.19
Other
Beta (Volatility)
0.30
Dividend Yield
3.23%
Does ABBV Have a Competitive Moat?
Sign in to unlockMoat Rating
🏰 Wide
Moat Trend
Stable
Moat Sources
4 Identified
AbbVie's wide moat is sustained by its robust pipeline and continuous innovation, allowing it to introduce new patented drugs (e.g., Skyrizi, Rinvoq) that replace revenue from expiring patents (e.g., Humira). The high cost and complexity of drug development, coupled with regulatory hurdles, create significant barriers to entry for new competitors.
Moat Erosion Risks
- •Patent Expirations for Future Blockbusters: While new drugs are replacing Humira, these too will face patent cliffs eventually, requiring continuous pipeline success.
- •Clinical Trial Failures: Late-stage pipeline failures for key assets could significantly impact long-term growth and erode future patent-derived moat sources.
ABBV Competitive Moat Analysis
Sign up to see competitive advantages
ABBV Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (No strong social media sentiment signals from the provided research; typical for a large, mature pharmaceutical company.)
Institutional Sentiment
Neutral (1,768 institutions added shares while 1,849 decreased positions in the most recent quarter, indicating balanced institutional activity with no clear strong bias.)
Insider Activity (Form 4)
Negative (4 insider sales and 0 purchases in the past 6 months, with no specific named transaction details provided in the search results.)
Options Flow
Normal options activity (No specific unusual options activity or put/call ratio direction was provided in the research).
Earnings Intelligence
Next Earnings
Estimated late July/early August 2026 (for Q2 2026)
Surprise Probability
Medium (Q1 2026 adjusted EPS met consensus, but revenue slightly missed. Guidance for Q2 2026 is tight with consensus.)
Historical Earnings Pattern
AbbVie generally delivers consistent earnings in line with or slightly above adjusted consensus, often providing stable guidance. Stock reaction typically reflects modest appreciation on beats and slight pullbacks on misses, with less volatility than high-growth companies.
Key Metrics to Watch
Competitive Position
Top Competitor
JNJ
Market Share Trend
Gaining market share in key immunology segments with Skyrizi and Rinvoq, effectively mitigating the impact of Humira biosimilar erosion.
Valuation vs Peers
Trading at a P/E multiple (approximately 15.2x forward P/E) generally in line with the mature pharmaceutical sector average, offering a stable valuation rather than a growth premium.
Competitive Advantages
- •Strong Intangible Assets (Extensive patent portfolio and regulatory exclusivities for blockbuster drugs like Skyrizi and Rinvoq)
- •Established Commercial Infrastructure (Global sales force and market access capabilities, particularly strong in immunology)
- •High Switching Costs (For patients on effective chronic therapies, switching carries risk and inconvenience, creating stickiness)
- •Diversified Pipeline (Beyond immunology, strong presence in oncology and neuroscience provides future growth drivers)
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive ABBV Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Release (Estimated late July/early August 2026): Confirmation of Q2 guidance for ~ $16.7B revenue and $3.74-$3.78 adjusted EPS, particularly strong operational growth for Skyrizi and Rinvoq, could provide positive momentum.
- •Continued Market Share Expansion of Skyrizi and Rinvoq (Ongoing): Sustained double-digit operational growth rates for these two key immunology drugs will be critical to offsetting Humira erosion and driving overall revenue increase.
Medium-Term (6-18 months)
- •Regulatory Approvals for New Indications (H2 2026 - H1 2027): Successful FDA/EMA approvals for pipeline assets or additional indications for Skyrizi/Rinvoq (e.g., in new inflammatory conditions) could unlock significant new patient populations and revenue streams, potentially adding $500M-$1B to peak sales each.
- •Advancement of Neurosciences Pipeline (2027): Positive Phase 3 readouts and subsequent regulatory submissions for key neuroscience assets could de-risk future growth beyond immunology and oncology, potentially addressing an additional ~$50B TAM.
Long-Term (18+ months)
- •Successful Launch of Next-Generation Blockbusters (2028-2029): Identification and successful commercialization of 1-2 new blockbuster drugs (>$5B peak sales) from its early-to-mid-stage pipeline, particularly in novel therapeutic areas, would be essential to maintaining growth post-2029.
- •Strategic M&A for Portfolio Diversification (2028-2029): Acquiring companies with strong, innovative pipelines in emerging high-growth biotech sectors could broaden AbbVie's therapeutic footprint and reduce reliance on immunology, generating new revenue streams upwards of $10B annually.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for ABBV?
- ✓
Watch for operational growth rates of Skyrizi and Rinvoq; if either consistently falls below 15% YoY, it may signal increased competitive pressure or slower adoption.
- ✓
Monitor any significant clinical trial failures or regulatory setbacks for AbbVie's late-stage pipeline assets (e.g., Phase 3 readouts in 2027), which could impact future growth prospects.
Bull Case Analysis
Sign up free to see the bull case
Competing with ABBV
See how AbbVie Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How AbbVie Inc Makes Money
AbbVie Inc. is a global biopharmaceutical company focused on developing and commercializing advanced therapies for complex and serious diseases. It generates revenue primarily by discovering, developing, manufacturing, and selling patented pharmaceutical products across several therapeutic areas, including immunology, oncology, neuroscience, and aesthetics. These products are sold to patients, healthcare providers, hospitals, and clinics worldwide, with a strong emphasis on prescription-based sales driven by the efficacy and intellectual property protection of its innovative drugs.
Read Full Business Model BreakdownFAQ
What is the DVR Score for AbbVie Inc (ABBV)?
As of May 24, 2026, AbbVie Inc has a DVR Score of 0.1 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of AbbVie Inc?
AbbVie Inc's market capitalization is approximately $381.1B. The company operates in the Healthcare sector within the Drug Manufacturers - General industry.
What ticker symbol does AbbVie Inc use?
ABBV is the ticker symbol for AbbVie Inc. The company trades on the NYQ.
What is the risk level for ABBV stock?
Our analysis rates AbbVie Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ABBV?
AbbVie Inc currently has a price-to-earnings (P/E) ratio of 104.8. This is above the market average, suggesting the stock may be priced for high growth expectations.
Does AbbVie Inc pay a dividend?
Yes, AbbVie Inc pays a dividend with a current yield of approximately 3.23%.
Is AbbVie Inc's revenue growing?
AbbVie Inc has reported revenue growth of 9.5%. The company is growing at a moderate pace.
Is ABBV stock profitable?
AbbVie Inc has a profit margin of 5.8%. The company is profitable but margins are modest.
How often is the ABBV DVR analysis updated?
Our AI-powered analysis of AbbVie Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 24, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ABBV (AbbVie Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.